Abstract
When making decisions about adjuvant chemotherapy for early-stage breast cancer, costs and benefits of treatment should be carefully weighed. In this process, patients’ preferences are of major importance. The objectives of the present study were: (1) to determine the minimum benefits that patients need to find chemotherapy acceptable, and (2) to explore potential preference determinants, namely: positive experience of the treatment, reconciliation with the treatment decision, and demographic variables. Preferences were elicited from patients scheduled for adjuvant chemotherapy (chemotherapy group: n = 38) before (T1), during (T2), and 1 month after chemotherapy (T3), and were compared to responses from patients not scheduled for chemotherapy (no-chemotherapy group: n = 38). The patients were asked, for a hypothetical situation, to indicate the minimum benefit (in terms of improved 5-year disease-free survival) to find adjuvant chemotherapy acceptable. In the chemotherapy group, the median benefit was 1% at all 3 measurement points. In the no-chemotherapy group the attitude towards chemotherapy became more negative over time, although not statistically significantly so (T1: 12%, T2: 15%, T3: 15%;P = 0.10). At all measurement points, the patients in the chemotherapy group indicated that they would accept chemotherapy for significantly (P< 0.01) less benefit than the patients in the no-chemotherapy group. Of the demographic variables, age was related to preferences, but only at T2and only in the no-chemotherapy group. The more positive attitude towards chemotherapy and the stability of preferences in the chemotherapy group indicated that reconciliation with the treatment decision was a more important determinant of patients’ preferences than positive experience of the treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bell DE (1982) Regret in decision making under uncertainty. Oper Res 30: 961–981
Berkowitz L (1986). A survey of social psychology (3rd ed), 64 Holt, Rinehart and Winston: New York
Brundage MD, Davidson JR and Mackillop WJ (1997) Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 15: 330–340
Cullen MH, Billingham LJ, Cook J and Woodroffe CM (1996) Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists. Br J Cancer 74: 1487–1491
Dodwell DJ (1998) Adjuvant cytotoxic chemotherapy for early breast cancer: doubts and decisions. Lancet 351: 1506–1507
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942
Elit LM, Levine MN, Gafni A, Whelan TJ, Doig G, Streiner DL and Rosen B (1996) Patients’ preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecologic Oncology 62: 329–335
Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B and Wickerham DL (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673–1682
Jansen SJT, Stiggelbout AM, Nooij MA and Kievit J (2000) The effect of individually assessed preference weights on the relationship between holistic utilities and nonpreference-based assessment. Quality Life Res 9: 541–557
Kiebert GM, Stiggelbout AM, Leer JWH, Kievit J and de Haes JCJM (1993) Test-retest reliabilities of two treatment-preference instruments in measuring utilities. Med Decis Making 13: 133–140
Levine MN, Guyatt GH Gent M, De Pauw S, Goodyear MD and Hryniuk WM (1988) Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6: 1798–1810
Levine MN, Gafni A, Markham B and MacFarlane D (1992) A bedside decision instrument to elicit a patient’s preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med 117: 53–58
Lindley C, Vasa S, Sawyer WT and Winer EP (1998) Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16: 1380–1387
Llewellyn-Thomas HA (1997) Investigating patients’ preferences for different treatment options. Can J Nurs Res 29: 45–64
Llewellyn-Thomas HA, Williams JI, Levy L and Naylor CD (1996) Using a trade-off technique to assess patients’ treatment preferences for benign prostatic hyperplasia. Med Decis Making 16: 262–272
McNeil BJ, Pauker SG, Sox HC Jr and Tversky A (1982) On the elicitation of preferences for alternative therapies. N Engl J Med 306: 1259–1262
McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B and Yellen SB (1995) Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 13: 858–868
Nieuwkerk PT, Hajenius PJ, Van der Veen F, Ankum WM, Wijker W and Bossuyt PM (1998) Systemic methotrexate therapy versus laparoscopic salpingostomy in tubal pregnancy. Part II. Patient preferences for systemic methotrexate. Fertility and Sterility 70: 518–522
O'Connor AM (1989) Effects of framing and level of probability on patients' preferences for cancer chemotherapy. J Clin Epidemiol 42: 119–126
Palda VA, Llewellyn-Thomas HA, Mackenzie RG, Pritchard KI and Naylor CD (1997) Breast cancer patients’ attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol 15: 3192–3200
Pritchard K (1997) Breast cancer: the real challenge. Lancet 349: sI24–sI26
Rajagopal S, Goodman PJ and Tannock IF (1994) Adjuvant chemotherapy for breast cancer: discordance between physicians’ perception of benefit and the results of clinical trials. J Clin Oncol 12: 1296–1304
Ravdin PM, Siminoff IA and Harvey JA (1998) Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16: 515–521
Sainsbury R, Rider L and Smith A MacAdam A, on behalf of the Yorkshire Breast Cancer Group (1995) Does it matter where you live? Treatment variation for breast cancer in Yorkshire. Br J Cancer 71: 1275–1278
Silvestri G, Pritchard R and Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317: 771–775
Siminoff LA and Fetting JH (1991) Factors affecting treatment decisions for a life-threatening illness: the case of medial treatment of breast cancer. Soc Sci Med 32: 813–818
Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM and Armes PJ (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300: 1458–1460
Stiggelbout AM, Kiebert GM, de Haes JC, Keizer HJ, Stoter G and de Wit RS (1996) Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis. Eur J Cancer 32A: 2267–2274
Stiggelbout AM, de Haes JC and van de Velde CJ (2000) Adjuvant chemotherapy in node negative breast cancer: patterns of use and oncologists' preferences. Ann Oncol 11: 631–633
Whelan TJ, Levine MN, Gafni A, Lukka H, Mohide EA, Patel M and Streiner DL (1995) Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol 13: 847–853
Yellen SB, Cella DF and Leslie WT (1994) Age and clinical decision making in oncology patients. J Natl Cancer Inst 86: 1766–1770
Yellen SB and Cella DF (1995) Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 13: 1255–1264
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jansen, S., Kievit, J., Nooij, M. et al. Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?. Br J Cancer 84, 1577–1585 (2001). https://doi.org/10.1054/bjoc.2001.1836
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1836